Cargando…
Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry
OBJECTIVE: To compare the clinical outcomes of patients with active immunoglobulin G (IgG) 4 related disease (IgG4-RD) receiving tocilizumab versus those receiving cyclophosphamide (CYC). METHODS: This IgG4-RD registry study was a prospective cohort study conducted among patients with active IgG4-RD...
Autores principales: | Zongfei, Ji, Lijuan, Zhang, Ying, Sun, Dongmei, Liu, Sifan, Wu, Xiufang, Kong, Lingying, Ma, Yun, Liu, Lili, Ma, Huiyong, Chen, Lindi, Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252355/ https://www.ncbi.nlm.nih.gov/pubmed/34262681 http://dx.doi.org/10.1177/20406223211028776 |
Ejemplares similares
-
Clinical and pathological predictors of relapse in IgG4-related disease
por: Zongfei, Ji, et al.
Publicado: (2022) -
In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease
por: Zongfei, Ji, et al.
Publicado: (2020) -
Single-Cell RNA-Sequencing Reveals Peripheral T Helper Cells Promoting the Development of IgG4-Related Disease by Enhancing B Cell Activation and Differentiation
por: Ji, Zongfei, et al.
Publicado: (2023) -
Serum IgG4 levels outperform IgG4/IgG RNA ratio in differential diagnosis of IgG4-related disease
por: Schulte, Lucas A., et al.
Publicado: (2020) -
IgG4-related disease: why high IgG4 and fibrosis?
por: Koike, Takao
Publicado: (2013)